Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases

• Published in: Digestive diseases and sciences Vol. 63; no. 2; pp. 302 - 311
• Main Authors: Yang, Xiaoxiao, Li, Yueyue, Sun, Yiyuan, Zhang, Mingming, Guo, Chuanguo, Mirza, Iqtida Ahmed, Li, Yan-Qing
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2018; Springer; Springer Nature B.V
• Subjects: Acids; Adenosine triphosphatase; Antiulcer drugs; Biochemistry; Care and treatment; Gastroenterology; Gastroesophageal reflux; Health aspects; Health risk assessment; Hepatology; Medicine; Medicine & Public Health; Oncology; Peptic ulcer; Review; Transplant Surgery; GERD; Vonoprazan; Peptic ulcers; Acid inhibitor; eradication; H. pylori eradication
• ISSN: 0163-2116; 1573-2568
• DOI: 10.1007/s10620-017-4866-6

Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K + from binding to gastric H + /K + -ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori ( H. pylori ) infection in Japan. The healing rate of GERD and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI-resistant GERD. It increases H. pylori eradication rate to more than 88% as part of both first-line and second-line therapy. It is also effective in the eradication of clarithromycin-resistant H. pylori strains. All of these short-term studies show vonoprazan is safe and well-tolerated. As a safe and effective acid inhibitor, vonoprazan might be a novel alternative in the treatment of acid-related diseases.